Medrogestone

Medrogestone: Overview

Medrogestone belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins, and derivatives. Chemically, it is a progestational agent derived from 17-methylprogesterone, also known as 6,17α-dimethyl-6-dehydroprogesterone. In clinical practice, medrogestone functions as a synthetic progestin to regulate menstrual cycles and control abnormal uterine bleeding. It has been used as an adjunct to manage secondary amenorrhea (absence of menstruation), induce menses, and treat dysfunctional uterine bleeding in adult and adolescent females. Additionally, it has been used in menopausal women to manage endometrial shedding in hormone replacement regimens. Originally developed by Ayerst and approved in Canada in 1969, its marketing status was later cancelled, and it was never approved by the US FDA.

Key Facts Summary:

Medrogestone: What Is It & How Does It Work?

Medrogestone exerts its pharmacological effects by mimicking natural progesterone and interacting with key hormone receptors in target tissues:

• Progesterone Receptor Binding: As a progestogen, medrogestone binds directly to and activates the progesterone receptor. This transforms the proliferative endometrium (induced by estrogen) into a secretory endometrium, helping stabilize the uterine lining and regulate shedding.
• Gonadotropin Suppression: It exerts a negative feedback effect on the anterior pituitary gland, suppressing the secretion of gonadotropic hormones (LH and FSH). In males, this leads to a secondary suppression of testicular testosterone production.
• Androgen Receptor Competition: Due to structural similarities to testosterone, medrogestone can compete for androgen-receptor binding sites in prostatic cells. This action, combined with a reduction in steroid hormone receptors, produces antiproliferative or cytotoxic effects in certain hormone-dependent cells.

Medrogestone: FDA Approval & Uses

Understanding the regulatory status of medrogestone clarifies its historical scope in progestin therapy and uterine bleeding management.

Global Regulatory Status

No. Medrogestone is Not Approved by the US Food and Drug Administration (FDA) for commercial distribution in the United States. While it was historically approved in Canada (under brand names like Colprone) and marketed in select European countries, its approval status in Canada was cancelled post-marketing.

Primary Indications

Historically, medrogestone was indicated for the following clinical purposes:

• Dysfunctional Uterine Bleeding: Used to control abnormal, irregular menstrual bleeding in adult and adolescent women.
• Secondary Amenorrhea: Administered as an adjunct or primary agent to induce withdrawal bleeding in women whose periods have stopped.
• Endometrial Shedding: Utilized in menopausal women receiving estrogen therapy to induce cyclic shedding of the uterine lining and prevent endometrial overgrowth.

Before Taking Medrogestone: Contraindications & Precautions

Before reviewing or taking medrogestone, key safety precautions and underlying health risks must be evaluated with a healthcare provider.

Who Should Not Take Medrogestone?

• Individuals with a known hypersensitivity or allergic reaction to medrogestone or any components of its formulation.
• Women with active thromboembolic disorders, severe deep vein thrombosis (DVT), pulmonary embolism, or a recent history of stroke or myocardial infarction.
• Patients with known or suspected estrogen- or progesterone-dependent malignancies, such as breast cancer or uterine cancer.
• Individuals with undiagnosed abnormal genital bleeding or severe hepatic (liver) impairment.

Medrogestone: Pregnancy & Breastfeeding

Medrogestone is strictly contraindicated during pregnancy. Exogenous progestins can cause adverse fetal development, including potential genital abnormalities. Progestational agents are excreted in human breast milk; therefore, it should not be used by nursing mothers.

Tell Your Doctor Before Taking Medrogestone

Inform your healthcare provider if you have a history of liver disease, blood clotting disorders, severe depression, hypertension, or cardiovascular disease prior to taking progestin therapy.

Medrogestone: Dosage & Administration

Because medrogestone is a synthetic progestin used for menstrual and endometrial regulation, historical dosing relied on cyclic oral schedules.

Standard Medrogestone Dosing

• Secondary Amenorrhea and Dysfunctional Bleeding: Historically administered orally in daily doses for a set duration (typically 5 to 10 days) of a cycle to induce withdrawal bleeding.

How Medrogestone Is Administered

• Dosage Forms: Supplied historically as oral Tablets (e.g., 5 mg single-ingredient tablets or combination coated tablets with conjugated estrogens).
• Administration Routes: Administered via the Oral route, typically taken with food or water to minimize gastric discomfort.

Medrogestone: Clinical Efficacy & Research

Historical clinical trials and endocrinology studies establish the efficacy of synthetic progestational agents. Research highlights its capacity to induce secretory conversion of the endometrium and suppress pituitary gonadotropin secretion.

Trial Findings and Efficacy

Historical clinical literature demonstrated that medrogestone was effective in controlling dysfunctional uterine bleeding and reliably inducing secretory transformation of the endometrium. Its progestational activity was sufficient to protect against uninhibited estrogen stimulation. However, with the development of newer, more targeted progestins with improved pharmacokinetic and side-effect profiles, market demand decreased, leading to its eventual withdrawal in several countries.

Medrogestone: Side Effects & Safety Profile

Understanding the side effect profile of medrogestone helps clinical teams evaluate its historical risk factors. The safety considerations for medrogestone are typical of synthetic progestational agents.

Common Medrogestone Side Effects

• Breakthrough bleeding, spotting, or changes in menstrual flow.
• Breast tenderness or enlargement.
• Nausea, abdominal cramps, and bloating.
• Headaches, mood swings, or fatigue.
• Mild weight gain or fluid retention.

Serious Medrogestone Adverse Events

• Thromboembolic Events: Increased risk of deep vein thrombosis, pulmonary embolism, and stroke.
• Hepatic Dysfunction: Potential liver enzyme elevations or jaundice in susceptible individuals.
• Severe Hypersensitivity: Rare allergic reactions including skin rash, urticaria, or anaphylaxis.

Managing Medrogestone Side Effects

If severe side effects such as sudden chest pain, shortness of breath, severe leg swelling, or unexpected severe headaches occur, the medication should be stopped immediately, and emergency medical evaluation sought.

Medrogestone: Drug Interactions & What to Avoid

Medrogestone is metabolized primarily by hepatic CYP3A4 pathways, interacting with enzymatic inducers and inhibitors.

Key Medrogestone Interactions

• CYP3A4 Inducers: Medications such as rifampin, carbamazepine, phenytoin, and St. John’s Wort accelerate the liver’s breakdown of medrogestone, potentially decreasing its clinical efficacy and causing breakthrough bleeding.
• CYP3A4 Inhibitors: Drugs such as ketoconazole, erythromycin, or clarithromycin can inhibit its metabolism, leading to elevated serum levels and an increased risk of side effects.

Medrogestone: Food & Alcohol

There are no major specific food interactions, but taking oral doses with meals can reduce mild nausea. Excessive alcohol consumption should be avoided as it can affect liver function and alter the clearance of steroid hormones.

Medrogestone: Missed Dose, Overdose & Storage

Proper handling, administration timing, and storage protocols govern progestin management.

Missed Dose of Medrogestone

If a dose was missed, patients were advised to take it as soon as remembered. If it was nearly time for the next scheduled dose, the missed dose was skipped. Doubling up on doses was avoided, as it could cause nausea or unexpected spot bleeding.

Medrogestone: Overdose

An acute overdose of progestins is generally non-life-threatening. Symptoms of overdosage typically include severe nausea, vomiting, breast tenderness, dizziness, and subsequent withdrawal bleeding in females. Management consists of supportive care.

How to Store Medrogestone

Store tablets at controlled room temperature, protected from excessive heat, moisture, and direct light. Keep out of reach of children.

Medrogestone: Patient Management & Guidelines

Effective clinical management relies on pre-treatment pelvic examinations and routine hepatic function monitoring.

Tests Before & During Medrogestone Treatment

• Baseline Pelvic Exam: Thorough physical and pelvic examinations to rule out genital malignancies or pregnancy before starting therapy.
• Hepatic Function Monitoring: Regular liver function testing for patients requiring prolonged progestin therapy.

Medrogestone: Do’s and Don’ts

• Do recognize that medrogestone is a cancelled/withdrawn agent in many regions and is generally no longer available in standard pharmacy settings.
• Do consult a gynecologist for modern, approved progestin alternatives if managing menstrual irregularities or hormone therapy.
• Do not take this medication if you are pregnant or experience undiagnosed abnormal vaginal bleeding.

Frequently Asked Questions

References

• DrugBank Database – Medrogestone Clinical and Pharmacological Profile
• Health Canada Drug Product Database (Discontinued/Cancelled Status for Colprone)
• Clinical Literature on Synthetic Progestational Agents in Gynecology

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider regarding medical conditions or treatment plans.